Advertisement

Topics

Destiny Pharma Ltd Company Profile

13:45 EST 23rd November 2017 | BioPortfolio

Destiny Pharma is a UK based anti-infectives pharmaceutical company founded, in 1997, by pharma industry executives. The company has developed and patented a portfolio of novel drugs that have a completely different mode of action from conventional antibiotics. These compounds (codenamed XF Drugs) have been shown to work in such a way that minimizes the development of bacterial resistance to repeated dosing. Our compounds can therefore be used to prevent and treat “superbugs” such as methicillin-resistant Staphylococcus aureus (MRSA); one of the major unmet needs of western medicine.

Location

at the Sussex Innovation Centre Science Park Square, Falmer
Brighton
BN1 9SB
United Kingdom

Contact

Phone: 44 (0) 1273 704 440
Fax: 44 (0) 1273 704 499
Email: enquiries@destiny-pharma.demon.co.uk


News Articles [586 Associated News Articles listed on BioPortfolio]

Destiny Pharma nets £14mm in IPO

Infectious disease-focused Destiny Pharma has gone public on the London Stock Exchange, netting £14mm ($18mm) through a placing of 9.73mm ordinary shares at £1.57 with existing and new institutional...

UK's Destiny Pharma Taps AIM Market to Fund 'Superbug' Drugs

British biotech firm Destiny Pharma is aiming to raise more than 10 million pounds ($12.9 million) of new equity to develop drugs that target antibiotic-resistant bacterial infections, or superbugs, i...

Destiny Pharma Floats on UK AIM And Completes China Deal

An agreement covering the development and commercialization of its products in China underlines the potential of now-publicly listed Destiny Pharma’s...   

Destiny Pharma Seeks AIM Listing To Advance First-In-Class Antibiotics

UK-based Destiny Pharma hopes its planned IPO will attract investor demand, backed by its promise of new anti-microbial drugs and...    

Destiny Pharma listed on London Stock Exchange

Brighton, UK-based Destiny Pharma has been successfully listed shares on London Stock Exchange with a market capitalisation of £65.4 million, marking the second biotech company to float this year in ...

Destiny Pharma partners with China Medical System Holdings

Destiny Pharma licensed China Medical System Holdings Ltd. rights to develop and commercialize its anti-infective assets in China and certain other Asian countries with the exception of Japan.

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Destiny Pharma has started trading on the London Stock Exchange to support its search for new antibiotics that can fight resistant bacteria like MRSA. Destiny Pharma, based in Brighton, UK, has entere...

The way to stay in destiny pdf

then people were full of faith and had reverence for the scriptures. isn’t Amway Corporation the big winner in this scheme? Some of these lessons were helpful, If you know you’re in a mood...

Drugs and Medications [238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [32 Associated PubMed Articles listed on BioPortfolio]

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Clinical Trials Series - Large Pharma.

AI-powered drug discovery captures pharma interest.

Endocytosis of tight junction proteins and the regulation of degradation and recycling.

Internalization of tight junction (TJ) proteins from the plasma membrane is a pivotal mechanism regulating TJ plasticity and function in both epithelial and endothelial barrier tissues. Once internali...

Clinical Trials [78 Associated Clinical Trials listed on BioPortfolio]

Diafert for Embryo Selection and Fertility Improvement (DESTINy)

Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

Companies [726 Associated Companies listed on BioPortfolio]

Destiny Pharma Ltd

Destiny Pharma is a UK based anti-infectives pharmaceutical company founded, in 1997, by pharma industry executives. The company has developed and patented a portfolio of novel drugs that have a compl...

Destiny Pharma

Destiny Pharma offers a custom research service where tailor made research studies are constructed and performed to the specific requirements of each client.Destiny Pharma specialise in:- Formulation ...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

Laurantis Pharma Oy

Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies, ...

More Information about "Destiny Pharma Ltd" on BioPortfolio

We have published hundreds of Destiny Pharma Ltd news stories on BioPortfolio along with dozens of Destiny Pharma Ltd Clinical Trials and PubMed Articles about Destiny Pharma Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Destiny Pharma Ltd Companies in our database. You can also find out about relevant Destiny Pharma Ltd Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record